BRAF and melanoma: reveal the relationship between the TME and drug tolerance in BRAF‐mutant melanoma treated with a BRAF inhibitor (BRAFi) through intravital imaging of cells via an ERK/MAPK biosensor: the inhibition of BRAF leads to paradoxical activation of CAFs and matrix remodeling.